, , 2006.
The basic principles of chimeric antigen receptor (CAR) design. Cancer Discov, avr, vol.3, issue.4, pp.388-98, 2013. ,
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond, Trends Mol Med. mai, vol.23, issue.5, pp.430-50, 2017. ,
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist, The Oncologist. mai, vol.21, issue.5, pp.608-625, 2016. ,
Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells, Disponible sur, vol.257, 2014. ,
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc Natl Acad Sci, vol.90, issue.2, pp.720-724, 1993. ,
CD28 costimulation: from mechanism to therapy, Immunity. 17 mai, vol.44, issue.5, pp.973-88, 2016. ,
Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptorderived C regions, Biochem Biophys Res Commun. 31 déc, vol.149, issue.3, pp.960-968, 1987. ,
Increasing the safety and efficacy of chimeric antigen receptor T cell therapy, Protein Cell. août, vol.8, issue.8, pp.573-89, 2017. ,
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.12, issue.20, pp.6106-6121, 2006. ,
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood. 15 sept, vol.112, issue.6, pp.2261-71, 2008. ,
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR? /CD28 receptor, Nat Biotechnol. janv, vol.20, issue.1, pp.70-75, 2002. ,
, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia, N Engl J Med. 25 août, vol.365, issue.8, pp.725-758, 2011. ,
TRUCKs: the fourth generation of CARs, Expert Opin Biol Ther, vol.15, issue.8, pp.1145-54, 2015. ,
Clinical manufacturing of CAR T cells: foundation of a promising therapy, Mol Ther Oncolytics, vol.3, p.16015, 2016. ,
,
,
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies, J Hematol OncolJ Hematol Oncol. 31 janv, vol.10, issue.1, p.35, 2017. ,
, Universal Chimeric Antigen Receptors | Cellectis
Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia, p.17 ,
Driving CAR T-cells forward, Nat Rev Clin Oncol. juin, vol.13, issue.6, pp.370-83, 2016. ,
, Primary Mediastinal Large B-Cell Lymphoma. The Oncologist. 5 janv, vol.11, issue.5, pp.488-95, 2006.
Estimation nationale de l'incidence et de la mortalité par cancer en France entre, p.136, 1980. ,
Estimation nationale de l'incidence des cancers en France entre 1980 et 2012 / 2013 / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil, vol.88, 2013. ,
, HAS. Avis de la CT du 12 décembre 2018 -KYMRIAH (tisagenlecleucel), CAR T anti-CD19 (LDGCB)
, HAS. Avis de la CT du 05 décembre 2018 -YESCARTA (axicabtagene ciloleucel), CAR T anti-CD19
, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019
Prise en charge du lymphome B diffus à grandes cellules en 2012, Rev Médicale Suisse, vol.9, 2012. ,
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 1 sept, vol.26, issue.suppl_5, pp.116-141, 2015. ,
Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy, Ann Hematol, vol.94, issue.5, pp.803-815, 2015. ,
High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort, Blood. 7 déc, vol.130, issue.1, pp.581-581, 2017. ,
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N Engl J Med. 28 déc, vol.377, issue.26, pp.2531-2575, 2017. ,
, R/R AGGRESSIVE NHL, 2018.
L'émergence des traitements par cellules CAR-T dans les lymphomes, Bull Cancer (Paris). 1 déc, vol.105, pp.168-77, 2018. ,
, Updated Analysis of JULIET Trial: Tisagenlecleucel in Relapsed or Refractory DLBCL -The ASCO Post, 2018.
Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Blood. 7 déc, vol.130, issue.1, pp.577-577, 2017. ,
, Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of lisocel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO
, HAS. Avis de la CT du 12 décembre 2018 -KYMRIAH (tisagenlecleucel), CAR T anti-CD19 (LAL)
Treatment of Pediatric Acute Lymphoblastic Leukemia, Pediatr Clin North Am. févr, vol.62, issue.1, pp.61-73, 2015. ,
Characterization of Pediatric Acute Lymphoblastic Leukemia Survival Patterns by Age at Diagnosis, J Cancer Epidemiol, 2014. ,
, Leucémie lymphoblastique aiguë
,
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study, J Clin Oncol. 5 janv, vol.27, issue.6, pp.911-919, 2009. ,
, Pronostic et survie pour la leucémie aiguë lymphoblastique -Société c
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia, Haematologica. 1 sept, 2016. ,
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 7 avr, p.25, 2016. ,
Acute lymphocytic leukemia, Hématologie. 1 mars, vol.20, issue.2, pp.116-145, 2014. ,
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group, Blood. 1 mars, vol.111, issue.5, pp.2548-55, 2008. ,
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N Engl J Med. 1 févr, vol.378, issue.5, pp.439-487, 2018. ,
Traitement par CAR-T des leucémies aiguës de l'adulte, Bull Cancer (Paris). 1 déc, vol.105, pp.158-67, 2018. ,
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet Lond Engl. 7 févr, vol.385, issue.9967, pp.517-545, 2015. ,
, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019
White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma -Full Text View -ClinicalTrials.gov ,
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest. 25 avr, vol.126, issue.6, pp.2123-2161, 2016. ,
, Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia -Full Text View -ClinicalTrials
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci Transl Med. 25 janv, vol.9, issue.374, p.2013, 2017. ,
, Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia -Full Text View -ClinicalTrials.gov [Internet
, Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia -Full Text View -ClinicalTrials.gov
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood. 22 juin, vol.129, issue.25, pp.3322-3353, 2017. ,
, A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia -Full Text View -ClinicalTrials.gov
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia, N Engl J Med, vol.31, 2018. ,
,
, Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 -Full Text View -ClinicalTrials.gov
,
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells, Blood. 1 janv, 2019. ,
, Putting a number on CAR-T deaths
,
, Juno: we could have saved JCAR015
,
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia, Cell. 31 mai, vol.173, issue.6, pp.1439-1453, 2018. ,
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells ,
,
Adera meeting, Les CAR T anti CD123 dans les leucémies aiguës myéloblastiques et les leucémies aiguës à cellules dendritiques, 2019. ,
CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib, Leukemia, vol.32, issue.5, pp.1168-79, 2018. ,
,
Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique Myélome multiple ,
, , 2009.
Hématologie clinique et biologique. Arnette, vol.578, 2006. ,
, Cancers du sang -Hémopathies -Myélome Multiple (MM) -Maladie -Avant propos
, Le myélome multiple : points clés -Comprendre le myélome multiple
,
Hématologie en pratique clinique Guide de diagnostic et de traitement. Médecine-Sciences Flammarion, LAVOISIER MSP, 2007. ,
, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019
Bleeding and Thrombosis in Multiple Myeloma and Related Plasma Cell Disorders, Semin Thromb Hemost, vol.37, issue.8, pp.929-974, 2011. ,
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J Clin Oncol, vol.33, issue.26, pp.2863-2872, 2015. ,
International staging system for multiple myeloma, J Clin Oncol Off J Am Soc Clin Oncol. 20 mai, vol.23, issue.15, pp.3412-3432, 2005. ,
Fiche information patient -Myélome multiple, 2009. ,
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation, Blood. 9 juin, vol.117, issue.23, pp.6063-73, 2011. ,
IMWG consensus on maintenance therapy in multiple myeloma, Blood. 29 mars, vol.119, issue.13, pp.3003-3018, 2012. ,
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation, J Clin Oncol Off J Am Soc Clin Oncol. 20 févr, vol.32, issue.6, pp.587-600, 2014. ,
, , pp.99-105, 2008.
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
, CAR T Cell Therapy in Heavily Pretreated Patients With Myeloma -The ASCO Post
, Study of bb2121 in Multiple Myeloma -Full Text View -ClinicalTrials.gov [Internet
, Meeting Library | bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study
,
, Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
, Disponible sur
, LEGEND-2 trial: phase I results using LCAR-B38M CAR-T therapy for patients with relapsed refractory multiple myeloma
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma, J Hematol OncolJ Hematol Oncol. 20 déc, vol.11, issue.1, p.141, 2018. ,
, LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma -Full Text View -ClinicalTrials.gov [Internet
, CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma -Full Text View -ClinicalTrials, A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell
,
Les CAR T dans le myélome multiple ,
Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy, Blood, vol.132, issue.1, pp.488-488, 2018. ,
, Study of bb21217 in Multiple Myeloma -Full Text View -ClinicalTrials.gov
Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE), Blood, vol.132, issue.1, pp.957-957, 2018. ,
, Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma -Full Text View -ClinicalTrials.gov
Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM), Blood, vol.132, issue.1, pp.1012-1012, 2018. ,
, 101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) -Full Text View -ClinicalTrials.gov
Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma, Blood, vol.132, issue.1, pp.960-960, 2018. ,
, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019
, CARsgen Therapeutics' IND for CT053 Receives Clearance in China
,
, Hrain Receives Another Clinical Trial Approval in Multiple Myeloma, Leading Chin -Hrain News -??????????????
, BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma -Full Text View -ClinicalTrials.gov [Internet
Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma, Blood, vol.132, issue.1, pp.956-956, 2018. ,
, Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT -Full Text View -ClinicalTrials.gov
Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study, Blood, vol.132, issue.1, pp.1009-1009, 2018. ,
, Multiple Myeloma Pipeline Filled With CAR T-Cell Therapies -The ASCO Post
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma, Sci Transl Med. 18 févr, vol.7, issue.275, pp.275-297, 2015. ,
Chimeric antigen receptor T cells: a novel therapy for solid tumors, J Hematol OncolJ Hematol Oncol, vol.29, issue.1, p.78, 2017. ,
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer, Sci China Life Sci. mai, vol.59, issue.5, pp.468-79, 2016. ,
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity, J Immunol Baltim Md, vol.183, issue.9, pp.5563-74, 1950. ,
, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2, Mol Ther. avr, vol.18, issue.4, pp.843-51, 2010. ,
Mesothelinspecific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol Res. févr, vol.2, issue.2, pp.112-132, 2014. ,
Chimeric antigen receptor T-cell therapy for solid tumors, Mol Ther Oncolytics. 13 avr, vol.3, p.16006, 2016. ,
New Strategies for the Treatment of Solid Tumors with CAR-T Cells, Int J Biol Sci. 28 avr, vol.12, issue.6, pp.718-747, 2016. ,
Trafficking of T cells into tumors, Cancer Res. 15 déc, vol.74, issue.24, pp.7168-74, 2014. ,
Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors, Cancer Res. 15 sept, vol.74, issue.18, pp.5195-205, 2014. ,
The landscape of CAR T-cell therapy in the United States and China: A comparative analysis, Int J Cancer. 15 avr, vol.144, issue.8, pp.2043-50, 2019. ,
, Disponible sur
Prise en charge des cellules CAR-T au sein des établissements de santé français : fabrication, distribution, et aspects réglementaires, 2018. ,
, ANSM. Les médicaments de thérapie innovante (MTI, ATMP) -ANSM : Agence nationale de sécurité du médicament et des produits de santé
,
, Haut Conseil des biotechnologies. Manuel du HCB pour l'utilisation confinée d'organismes génétiquement modifiés
, Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique | Mélissa BEIGNON |2019
, Déclaration d'utilisation ou demande d'agrément d'utilisation d'O.G.M. en milieu confiné à des fins de recherche, de développement et d'enseignement
, Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
Rôle du pharmacien hospitalier dans le circuit d'une catégorie de Médicament de Thérapie Innovante : les lymphocytes T exprimant un Récepteur Chimérique à l'Antigène, Bull Cancer (Paris). 1 déc, vol.105, pp.205-218, 2018. ,
Toxicity and management in CAR Tcell therapy, Mol Ther Oncolytics, vol.3, p.16011, 2016. ,
Genetically modified T cells in cancer therapy: opportunities and challenges, Dis Model Mech. avr, vol.8, issue.4, pp.337-50, 2015. ,
Current concepts in the diagnosis and management of cytokine release syndrome, Blood. 10 juill, vol.124, issue.2, pp.188-95, 2014. ,
The safety and side effects of monoclonal antibodies, Nat Rev Drug Discov. avr, vol.9, issue.4, pp.325-363, 2010. ,
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia, Sci Transl Med. 19 févr, vol.6, issue.224, pp.224-249, 2014. ,
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med. 2 sept, vol.7, issue.303, pp.303-139, 2015. ,
Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 30 juin, vol.127, pp.3321-3351, 2016. ,
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, N Engl J Med, vol.371, issue.16, pp.1507-1524, 2014. ,
EPAR -public assessment report.pdf [Internet], 2018. ,
EPAR -public assessment report.pdf [Internet], 2018. ,
, The EBMT Patient Registry
,
, MACRO Database Training
,
, Lymphome | The Lymphoma Study Association
,
, Arrêté du 30 avril 2019 subordonnant la prise en charge d'un médicament par l'assurance maladie au recueil et à la transmission de certaines informations relatives à sa prescription
, Missions et domaines d'intervention -Qui sommes nous ?
,
L'autorisation d'utilisation de cellules CAR T par les centres français, 2019. ,
, Arrêté du 28 mars 2019 limitant l'utilisation de médicament de thérapie innovante à base de lymphocytes T génétiquement modifiés dits CAR-T Cells autologues indiqués dans le traitement de la leucémie aiguë lymphoblastique à cellules B et/ou du lymphome à grande cellule B, à certains établissements de santé en application des dispositions de l'article L. 1151-1 du code de la santé publique
Le CAR T dans la pratique clinique : mise en place du parcours patient. Adera meeting, 2019. ,
, Code de la santé publique -Article L5126-5. Code de la santé publique
, Autorisations d'activités portant sur les médicaments de thérapie innovante préparés ponctuellement (MTI PP) -ANSM : Agence nationale de sécurité du médicament et des produits de santé
Le rôle du pharmacien dans la mise en place des thérapies par CAR T à l'hôpital, 2019. ,
Prérequis nécessaires pour la mise en place de protocoles de recherche clinique évaluant des thérapies cellulaires et géniques par lymphocytes T dotés de récepteur chimérique à l'antigène (CAR T-cells) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bull Cancer, vol.104, issue.12, pp.43-58, 2017. ,
, Arrêté du 14 septembre 2009 fixant le contenu du dossier accompagnant la demande d'autorisation ou la demande de renouvellement d'autorisation d'effectuer des prélèvements de cellules à des fins thérapeutiques
, des dossiers de demandes d'autorisation ou de renouvellement d'autorisation des activités relatives aux tissus, à leurs dérivés, aux cellules et aux préparations de thérapie cellulaire
, Notice technique PMSI 2019 | Publication ATIH
,
, 27Z024 Allogreffes de cellules souches hématopoïétiques
, Haute Autorité de Santé -Avis n° 2019.0011/AC/SEAP du 27 février 2019 du collège de la HAS relatif à l'inscription sur la LAP mentionnée à l'article L. 162-1-7 du CSS, des actes associés au traitement par CAR-T Cells
, ATIH. Notice technique ATIH. Les nouveautes du financement 2019
,
, 17M084 Leucémies aigües, âge inférieur à 18 ans, niveau 4 -Code GHM
, 17M154 Lymphomes et autres affections malignes... -Code GHM
Circuit pharmaceutique des CAR T cells au CHU de Bordeaux. Adera meeting; 2019 mars 13 ,
Traitement par cellules CAR-T : état des lieux de leur utilisation aux États-Unis en, Bull Cancer (Paris). 1 déc, vol.105, pp.214-221, 2018. ,
, Risk Evaluation and Mitigation Strategies (REMS)
,
, Risk Evaluation and Mitigation Strategy (REMS
,
Dear Tweeps, I've been asked to review the current #CARTcell panorama in the US. If you are a hem/onc/BMT physician practicing in the US I would appreciate your insight: If you consider a patient for CD19 CAR-T cell tx would you favor (assuming insurance clearance): [Internet]. @drjgauthier. 2018T14:30 ,
, CAR-T Cell Therapy Program -Department home
, Mayo Clinic
,